Sight Sciences (SGHT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

07.11.25 01:30 Uhr

Werte in diesem Artikel

Sight Sciences, Inc. (SGHT) reported $19.91 million in revenue for the quarter ended September 2025, representing a year-over-year decline of 1.3%. EPS of -$0.16 for the same period compares to -$0.22 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $17.16 million, representing a surprise of +15.98%. The company delivered an EPS surprise of +38.46%, with the consensus EPS estimate being -$0.26.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Sight Sciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenue- Dry Eye: $0.19 million compared to the $0.25 million average estimate based on three analysts. The reported number represents a change of -87.7% year over year.Revenue- Surgical Glaucoma: $19.72 million versus $16.91 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.8% change.Gross Profit - Dry Eye: $0.07 million versus $0.13 million estimated by two analysts on average.Gross Profit - Surgical Glaucoma: $17.13 million compared to the $13.77 million average estimate based on two analysts.View all Key Company Metrics for Sight Sciences here>>>Shares of Sight Sciences have returned +45% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sight Sciences, Inc. (SGHT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Sight Sciences

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Sight Sciences

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Sight Sciences Inc Registered Shs

Wer­bung